Resubmit the NDA for reproxalap
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Feb 2024
- Due
- 31 Dec 2024
- Delivered
- 3 Oct 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Proposed clinical trial top-line results and potential NDA resubmission are expected in the second half of 2024”
What we found
Evidence strength A What the grades mean
The company successfully resubmitted the NDA for reproxalap on October 3, 2024, which falls within the second half of 2024.
-
A Aldeyra Therapeutics, Inc. 10-K filed 2025-02-28
“On October 3, 2024, Aldeyra announced resubmission of the NDA (the Resubmitted NDA)” ✓ confirmed on the page
Market reaction: the shares moved -1.3% against the S&P 500 over the three sessions around the disclosure (27 Feb 2025 to 4 Mar 2025). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 13 Feb 2024
Deadline 31 Dec 2024 (“second half of 2024”) · wording expected
-
Version 2 · stated 3 Apr 2025
Deadline 30 Jun 2025 (“mid-2025”) · wording expected
“Contingent on positive results and FDA discussions, NDA resubmission is anticipated mid-2025.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Resubmit
- Deliverable
- NDA resubmission for reproxalap
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: pending clinical trial results; feedback from ongoing FDA discussions
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-ALDX-003540 · Corrections policy